DOL Announces New LM-10 Guidance and Extended Filing Deadline
Client Alert | 1 min read | 03.09.06
On March 7, 2006, the U.S. Department of Labor ("DOL") issued new guidance on employers' LM-10 reporting requirements in the form of additional Frequently Asked Questions (FAQ) added to the DOL's Advisory and FAQ issued in November 2005.
The DOL's November 2005 Advisory indicated a much more aggressive enforcement posture with respect to LM-10 reporting, but also created a grace period for reporting -- employers who file compliant LM-10 forms within 90 days of the company's 2005 fiscal year will not be penalized for their failure to submit reports for any prior years. The revised FAQ announces that employers whose fiscal year ended December 31, 2005 will now have until May 15, 2006 to file their fiscal year 1005 LM-10s
The revised Advisory and FAQs clarify who must file annual LM-10 reports, provide additional examples of reportable expenditures, and explain how an employer who has no reportable expenditures for the 2005 fiscal year can still take advantage of the grace period. Unionized employers should carefully review the revised FAQ, as well as the underlying statutes and case law in this very complicated area of the law, to determine their reporting requirements and ensure that appropriate processes are in place to track reportable expenditures.
Contacts
Partner
She/Her/Hers
Insights
Client Alert | 4 min read | 04.18.24
Following federal lawmakers’ initiative to lower prescription drug prices under the Inflation Reduction Act of 2022, several states have taken similar steps to limit certain drugs’ prices. Drug affordability for consumers is a top priority for federal and state lawmakers and regulators because it is a bipartisan issue that directly impacts consumers’ wallets. With negotiations between the federal government and drug manufacturers over 10 drugs’ prices for Medicare beneficiaries well underway under the Inflation Reduction Act, 11 states, including Maryland and Colorado, have created drug affordability review boards to more directly tackle rising prices for both brand and generic drugs.[1] And another 12 states have pending legislation to create these boards.[2]
Client Alert | 6 min read | 04.16.24
Navigating the AI Intellectual Property Maze - Key Points From Congressional Hearing
Client Alert | 5 min read | 04.15.24
Making the EU Courts More Efficient for Trade-Related Decisions
Client Alert | 1 min read | 04.15.24
New FAR Part 40 to Address Supply Chain and Information Security Requirements
